Fox Chase Cancer Center News

PHILADELPHIA (December 16, 2019) – New research from Fox Chase Cancer Center has set the framework for gene therapy as a possible treatment for human cystathionine beta-synthase deficiency, the most common inborn error of metabolism found in children. “We showed that the DNA we treated was expressed in the liver and could reverse the phenotypes we observed in mice with CBS deficiency.”

PHILADELPHIA (December 16, 2019) – Almost one-third of patients with clear cell renal cell carcinoma (ccRCC) who underwent surgery for their cancer at Fox Chase Cancer Center were found to have a loss of the whole or a segment of chromosome 9. This was associated with several adverse disease characteristics and outcomes.

PHILADELPHIA (December 13, 2019) –  For the past 10 years, Fox Chase Cancer Center has served as one of six regional GMaP hubs and will be able to continue and expand its role with a new $500,000 grant from the National Cancer Institute.

PHILADELPHIA (December 13, 2019) – Robert Uzzo and colleagues found that type-2 papillary renal cell carcinomas were more likely to have lower pre-contrast attenuation than type-1 tumors.

PHILADELPHIA (December 11, 2019) – New research indicates that BRCA1 gene rearrangements are responsible for generating partially active proteins that drive the development of resistance to PARP inhibitors.

PHILADELPHIA (December 6, 2019) – The work of Sergei Grivennikov, PhD, is included in this year’s rankings by the Web of Science Group.

To make cancer screening more convenient for staff, Fox Chase Cancer Center kicked off its Employee Cancer Screening Initiative this October.

PHILADELPHIA (December 3, 2019) – Fox Chase Cancer Center researcher Jeffrey Peterson, PhD, has been awarded a $1.4 million grant by the U.S. Department of Defense to evaluate and exploit the mechanisms of inducing programmed cell death using polyunsaturated fatty acids in TNBC.